TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21627828

Group type: EXPERIMENTAL
Intervention: Salmeterol + Fluticasone Propionate (SFC)
Number of subjects: 4951

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4951

Group type: COMPARATOR
Intervention: Salmeterol alone
Number of subjects: 4951

Group type: COMPARATOR
Intervention: Fluticasone Propionate alone
Number of subjects: 4951

Group type: EXPERIMENTAL
Intervention: Overall health status deterioration
Number of subjects: 4951
Study: 19396632

Group type: EXPERIMENTAL
Intervention: ghrelin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GHRP-6
Number of subjects: 29

Group type: COMPARATOR
Intervention: controls
Number of subjects: 29
Study: 16533451

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 800 mug
Number of subjects: 450

Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 450
Study: 15300538

Group type: EXPERIMENTAL
Intervention: N‐butylcyanoacrylate (Indermil) adhesive bonds
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyglactin 5‐0 (Vicryl) sutures
Number of subjects: 100
Study: 11059998

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Clinical management (CM)
Number of subjects: 158
Study: 8340625

Group type: EXPERIMENTAL
Intervention: Lingual split method by chisel
Number of subjects: 52

Group type: COMPARATOR
Intervention: Buccal approach with surgical bur
Number of subjects: 52

Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 52
Study: 3519731

Group type: EXPERIMENTAL
Intervention: Streptokinase therapy (combined intravenous and intracoronary)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (standard coronary care unit treatment)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Streptokinase therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 31568390

Group type: EXPERIMENTAL
Intervention: Active intervention (lifestyle advice delivered by renal dietitians using behavior change techniques)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Passive intervention (leaflet advice alone)
Number of subjects: 130
Study: 28865057

Group type: EXPERIMENTAL
Intervention: Standard Roux-en-Y gastric bypass
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Distal Roux-en-Y gastric bypass
Number of subjects: 113
Study: 27174526

Group type: EXPERIMENTAL
Intervention: Edaravone (60 mg/d) administered from the day of surgery to postsurgical day 7
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no edaravone)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edaravone (60 mg/d)
Number of subjects: 72
Study: 25530054

Group type: EXPERIMENTAL
Intervention: Pray meditation for 20 minutes using a disposable phone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (phone off)
Number of subjects: 160
Study: 22414705

Group type: EXPERIMENTAL
Intervention: Propranolol (a beta adrenergic antagonist)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (sugar pill)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 27
Study: 19941990

Group type: EXPERIMENTAL
Intervention: CDA1 (10mg/kg intravenous infusion)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CDA1
Number of subjects: 46
Study: 18188758

Group type: EXPERIMENTAL
Intervention: Information-only (INF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sampling (SMP)
Number of subjects: 0
Study: 16186288

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily
Number of subjects: 3038

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3038
Study: 12594635

Group type: EXPERIMENTAL
Intervention: Lipid formulation of amphotericin B (L‐AmB), 10 mg/kg daily for 2 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lipid formulation of amphotericin B (L‐AmB), 4 mg/kg daily for 5 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Meglumine antimoniate
Number of subjects: 41
Study: 10556145

Group type: EXPERIMENTAL
Intervention: Gentamicin 160 mg via dry powder inhaler (DPI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gentamicin via small-volume nebulizer (SVN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gentamicin at 5 mg/kg by intravenous infusion
Number of subjects: 10
Study: 8737325

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.25 g creatine monohydrate per kg body mass)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (CON group)
Number of subjects: 19
Study: 1376482

Group type: EXPERIMENTAL
Intervention: Generalized linear model fitted on VPB counts for MI survivors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized linear model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of VPB counts
Number of subjects: 0
Study: 4000778

Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 93

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control infants without polycythemia
Number of subjects: 93
Study: 29651970

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27575717

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 25567010

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (HepB) administered on 0-1-6 schedule
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (HepB)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Anti-HBc alone (HepB)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (after first-dose revaccination)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Anti-HBc alone (after first-dose revaccination)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (after third-dose revaccination)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Anti-HBc alone (after third-dose revaccination)
Number of subjects: 228
Study: 22873342

Group type: EXPERIMENTAL
Intervention: Aloe vera gruel (30-40 mL daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Antiretroviral drugs
Number of subjects: 30
Study: 20415082

Group type: EXPERIMENTAL
Intervention: Manipulation (3 times a week for 3 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traction (5 to 6 kg, 20 minutes each time, once every other day) and Nimodipine (40 mg, 3 times a day for 3 weeks)
Number of subjects: 70
Study: 17903344

Group type: EXPERIMENTAL
Intervention: Calcium intake of 600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcium intake of 1200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium intake of 0 mg (control)
Number of subjects: 12
Study: 15790983

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Baseline FEV1 corrected for gas compression (NFEV1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rle and maximum transpulmonary pressure (TP(peak)) during the forced manoeuvre
Number of subjects: 27
Study: 12456919

Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein preterm infant formula (HPF)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard preterm infant formula (SPF)
Number of subjects: 129
Study: 10487455

Group type: EXPERIMENTAL
Intervention: Topical mupirocin therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical nystatin cream
Number of subjects: 20
Study: 8757375

Group type: EXPERIMENTAL
Intervention: Laparoscopic suture repair
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Laparoscopic sutureless repair
Number of subjects: 103

Group type: COMPARATOR
Intervention: Open suture repair
Number of subjects: 103

Group type: COMPARATOR
Intervention: Open sutureless repair
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (both suture and sutureless)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 103
Study: 1465747

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms, one puff twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6373050

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31155472

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injections
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 32
Study: 29369159

Group type: EXPERIMENTAL
Intervention: Tox+ for stimulants (methamphetamine or cocaine)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Substance use severity measured by the Addiction Severity Index
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tox+ for stimulants
Number of subjects: 84
Study: 26663359

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 872

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872
Study: 24561811

Group type: EXPERIMENTAL
Intervention: Resistive Exercise (RE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistive Vibration Exercise (RVE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inactive Control Group
Number of subjects: 24
Study: 22222478

Group type: EXPERIMENTAL
Intervention: Dual-loop control using a proportional-integral-derivative controller
Number of subjects: 61

Group type: COMPARATOR
Intervention: Skilled manual control of propofol and remifentanil using target-controlled-infusion systems
Number of subjects: 61
Study: 20570755

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study: 18154644

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Sustained-release oral morphine (SRM)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Both TDF and SRM
Number of subjects: 680
Study: 16217721

Group type: EXPERIMENTAL
Intervention: Speech Therapy Assessment (STA)
Number of subjects: 260
Study: 12017395

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Enteric-coated diclofenac sodium 50 mg (3 doses of 50 mg every 8 hours)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 10396581

Group type: EXPERIMENTAL
Intervention: CT scanning organization in Italian hospitals
Number of subjects: 179

Group type: COMPARATOR
Intervention: CT scanning organization in UK hospitals
Number of subjects: 179
Study: 7560118

Group type: EXPERIMENTAL
Intervention: Infant-centered intervention using the Brazelton Neonatal Behavioral Assessment Scale (NBAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mother-centered intervention consisting of an in-depth interview focused on mothers' concerns about parenting
Number of subjects: 0
Study: 2142700

Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 1.0 mg dexamethasone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 1.5 mg dexamethasone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 2.0 mg dexamethasone
Number of subjects: 119
Study: 6283873

Group type: EXPERIMENTAL
Intervention: High dietary fiber diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low dietary fiber diet
Number of subjects: 8
Study: 31382977

Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg/d + standard therapy for 4 days
Number of subjects: 255

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (in RTP cohort)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Genes associated with 1-year mortality
Number of subjects: 255
Study: 29958284

Group type: EXPERIMENTAL
Intervention: Dry-sheet TBW (DRY group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Wet-sheet TBW (WET group)
Number of subjects: 48
Study: 26498434

Group type: EXPERIMENTAL
Intervention: Gait rehabilitation for stroke patients with basal ganglia involvement and prior stroke
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Gait rehabilitation for stroke patients with lacunar infarctions
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Gait rehabilitation for stroke patients with right-hemisphere cortical involvement
Number of subjects: 408
Study: 24817374

Group type: EXPERIMENTAL
Intervention: SILS sleeve gastrectomy (SG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups (SILS and CLS)
Number of subjects: 28
Study: 22364374

Group type: EXPERIMENTAL
Intervention: Rowing (250-270 km · week⁻¹)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rowing plus weight-training (190-210 km · week⁻¹ + 4 sessions/week)
Number of subjects: 22
Study: 20186890

Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 267

Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 267
Study: 17505723

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 41
Study: 16321619

Group type: EXPERIMENTAL
Intervention: Oral alfentanil (23, 30, 43, or 75 microg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no CYP3A modulation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (intestinal CYP3A inhibition)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rifampin (CYP3A induction)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Troleandomycin (CYP3A inhibition)
Number of subjects: 20
Study: 11986452

Group type: EXPERIMENTAL
Intervention: Oral midazolam plus oral transmucosal fentanyl (5-10 microg/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral midazolam plus placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral midazolam plus oral transmucosal fentanyl
Number of subjects: 51
Study: 9535154

Group type: EXPERIMENTAL
Intervention: 60 mg urapidil orally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7893017

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine 0.4%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oxybuprocaine (3 drops)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine with cotton tip sticks
Number of subjects: 90
Study: 2761587

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg daily)
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Aspirin (1300 mg daily)
Number of subjects: 3069
Study: 323326

Group type: EXPERIMENTAL
Intervention: Bronkosol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoetharine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bronkosol and Isoetharine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylephrine added to Isoetharine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bronkosol, Isoetharine, and Phenylephrine
Number of subjects: 0
Study: 30855691

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study: 28445631

Group type: EXPERIMENTAL
Intervention: CBT with Exposure Therapy (CBT/Exposure)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CBT without Exposure Therapy (CBT)
Number of subjects: 80
Study: 26081486

Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened soft drinks (SSSDs) - 1 l daily for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Isocaloric semi-skimmed milk - 1 l daily for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Diet cola - 1 l daily for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Water - 1 l daily for 6 months
Number of subjects: 47
Study: 23820464

Group type: EXPERIMENTAL
Intervention: Current cannabis users (n=18)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Past cannabis users (n=33)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Never cannabis users (n=36)
Number of subjects: 87
Study: 21629012

Group type: EXPERIMENTAL
Intervention: Vignette describing a character with alcoholism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vignette describing a character with depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vignette describing a character with schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vignette describing a character with minor problems
Number of subjects: 0
Study: 19786163

Group type: EXPERIMENTAL
Intervention: Online risk assessment + feedback
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Online risk assessment + feedback (high-risk subjects)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control (high-risk subjects)
Number of subjects: 168
Study: 16699126

Group type: EXPERIMENTAL
Intervention: Nutrition education module (5 sessions)
Number of subjects: 703
Study: 15338971

Group type: EXPERIMENTAL
Intervention: 81 mg/day aspirin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 325 mg/day aspirin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 22

Group type: COMPARATOR
Intervention: baseline (no aspirin)
Number of subjects: 22
Study: 11341854

Group type: EXPERIMENTAL
Intervention: naloxone/lofexidine combination treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: lofexidine monotherapy
Number of subjects: 49
Study: 9403155

Group type: EXPERIMENTAL
Intervention: Alexithymics
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-alexithymics
Number of subjects: 24

Group type: COMPARATOR
Intervention: TAT card II
Number of subjects: 24
Study: 8216441

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/d
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 56
Study: 3109670

Group type: EXPERIMENTAL
Intervention: Combined clinic with a rheumatologist and an orthopaedic surgeon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orthopaedic clinic with an orthopaedic surgeon alone
Number of subjects: 0
Study: 28895379

Group type: EXPERIMENTAL
Intervention: Remifentanil at a target effect‐site concentration of 7 ng×mL‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Baseline SPI value in patients without pain
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maximal SPI value after intubation in patients receiving remifentanil
Number of subjects: 120
Study: 27282158

Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24566596

Group type: EXPERIMENTAL
Intervention: Transitional Care Clinic (TCC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 23942318

Group type: EXPERIMENTAL
Intervention: Music therapy (MT) plus treatment as usual (TAU)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 144
Study: 24843430

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in 2003
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in 2008
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Prediabetes prevalence in 2003
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Prediabetes prevalence in 2008
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Diabetes incidence rate
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Prediabetes incidence rate
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - Impaired fasting glucose (IFG)
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - Impaired glucose tolerance (IGT)
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - Age
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - Waist-to-hip ratio
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - Systolic blood pressure
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - Triglyceride
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Risk factor - Waist-to-hip ratio (after excluding IFG and IGT)
Number of subjects: 1806
Study: 17764606

Group type: EXPERIMENTAL
Intervention: Free iron/folic acid tablets (treatment, n = 109)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Prescription to purchase iron/folic acid tablets (control, n = 112)
Number of subjects: 221
Study: 17126666

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15238038

Group type: EXPERIMENTAL
Intervention: Moving to low-poverty neighborhoods
Number of subjects: 588
Study: 11411812

Group type: EXPERIMENTAL
Intervention: Sertraline treatment during the 24-week open-label continuation phase
Number of subjects: 128
Study: 9827122

Group type: EXPERIMENTAL
Intervention: Local solution based on 'pain de singe' (baobab fruit)
Number of subjects: 161

Group type: COMPARATOR
Intervention: WHO standard solution
Number of subjects: 161
Study: 8314474

Group type: EXPERIMENTAL
Intervention: 3 million units (MU) interferon three times weekly for six months
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 3 MU interferon three times weekly for the first six months, 2 MU for the next three months, and 1 MU for the last three months
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Patients without cirrhosis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Patients with cirrhosis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Longer treatment (12 months)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Shorter treatment (6 months)
Number of subjects: 111